| Azacitidine and venetoclax in previously untreated acute myeloid leukemia CD DiNardo, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, AH Wei, ... New England journal of medicine 383 (7), 617-629, 2020 | 2275 | 2020 |
| Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia CD DiNardo, K Pratz, V Pullarkat, BA Jonas, M Arellano, PS Becker, ... Blood, The Journal of the American Society of Hematology 133 (1), 7-17, 2019 | 1837 | 2019 |
| Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label … CD DiNardo, KW Pratz, A Letai, BA Jonas, AH Wei, M Thirman, ... The lancet oncology 19 (2), 216-228, 2018 | 760 | 2018 |
| AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) PP Zarrinkar, RN Gunawardane, MD Cramer, MF Gardner, D Brigham, ... Blood, The Journal of the American Society of Hematology 114 (14), 2984-2992, 2009 | 741 | 2009 |
| Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia F Ravandi, JE Cortes, D Jones, S Faderl, G Garcia-Manero, ... Journal of clinical oncology 28 (11), 1856-1862, 2010 | 487 | 2010 |
| Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology MS Tallman, ES Wang, JK Altman, FR Appelbaum, VR Bhatt, D Bixby, ... Journal of the National Comprehensive Cancer Network 17 (6), 721-749, 2019 | 465 | 2019 |
| Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology MR O'Donnell, MS Tallman, CN Abboud, JK Altman, FR Appelbaum, ... Journal of the National Comprehensive Cancer Network 15 (7), 926-957, 2017 | 447 | 2017 |
| Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide SR McCurdy, JA Kanakry, MM Showel, HL Tsai, J Bolaños-Meade, ... Blood, The Journal of the American Society of Hematology 125 (19), 3024-3031, 2015 | 332 | 2015 |
| FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML KW Pratz, T Sato, KM Murphy, A Stine, T Rajkhowa, M Levis Blood, The Journal of the American Society of Hematology 115 (7), 1425-1432, 2010 | 303 | 2010 |
| Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology MW Deininger, NP Shah, JK Altman, E Berman, R Bhatia, B Bhatnagar, ... Journal of the National Comprehensive Cancer Network 18 (10), 1385-1415, 2020 | 275 | 2020 |
| Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults YL Kasamon, J Bolaños-Meade, GT Prince, HL Tsai, SR McCurdy, ... Journal of Clinical Oncology 33 (28), 3152-3161, 2015 | 257 | 2015 |
| Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS CG Kanakry, HL Tsai, J Bolaños-Meade, BD Smith, I Gojo, JA Kanakry, ... Blood, The Journal of the American Society of Hematology 124 (25), 3817-3827, 2014 | 219 | 2014 |
| A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response KW Pratz, J Cortes, GJ Roboz, N Rao, O Arowojolu, A Stine, Y Shiotsu, ... Blood, The Journal of the American Society of Hematology 113 (17), 3938-3946, 2009 | 216 | 2009 |
| Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study EM Stein, CD DiNardo, AT Fathi, AS Mims, KW Pratz, MR Savona, ... Blood, The Journal of the American Society of Hematology 137 (13), 1792-1803, 2021 | 204 | 2021 |
| Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide SR McCurdy, YL Kasamon, CG Kanakry, J Bolaños-Meade, HL Tsai, ... Haematologica 102 (2), 391, 2017 | 193 | 2017 |
| Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML A Sexauer, A Perl, X Yang, M Borowitz, C Gocke, T Rajkhowa, C Thiede, ... Blood, The Journal of the American Society of Hematology 120 (20), 4205-4214, 2012 | 190 | 2012 |
| Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow‐up from a phase 1b study DA Pollyea, K Pratz, A Letai, BA Jonas, AH Wei, V Pullarkat, M Konopleva, ... American journal of hematology 96 (2), 208-217, 2021 | 147 | 2021 |
| Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias JE Karp, BM Thomas, JM Greer, C Sorge, SD Gore, KW Pratz, BD Smith, ... Clinical Cancer Research 18 (24), 6723-6731, 2012 | 136 | 2012 |
| Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine KW Pratz, BA Jonas, V Pullarkat, C Recher, AC Schuh, MJ Thirman, ... Journal of Clinical Oncology 40 (8), 855-865, 2022 | 135 | 2022 |
| HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation AM Zeidan, PM Forde, H Symons, A Chen, BD Smith, K Pratz, H Carraway, ... Biology of Blood and Marrow Transplantation 20 (3), 314-318, 2014 | 134 | 2014 |
